Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

Caroline O'Leary; Christopher Schultz; Cathal Walsh; Roisin Adams; Deborah Casey; Stephen Lane; Michael Harrison; Shane Doyle; Richard W Costello; Fionnuala King; Desmond M Murphy

doi:10.1136/bmjresp-2022-001341

Article info

Asthma

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

Authors

Caroline O'Leary Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland PubMed articles Google scholar articles
Christopher Schultz HSE Acute Operations, Quality and Patient Safety, Dublin, Ireland PubMed articles Google scholar articles
Cathal Walsh Acute Hospitals Drugs Management Programme, Dublin, Ireland PubMed articles Google scholar articles
Roisin Adams Acute Hospitals Drugs Management Programme, Dublin, Ireland PubMed articles Google scholar articles
Deborah Casey Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland PubMed articles Google scholar articles
Stephen Lane Department of Respiratory Medicine, Tallaght University Hospital & Peamount Healthcare, Dublin, Ireland PubMed articles Google scholar articles
Michael Harrison Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland PubMed articles Google scholar articles
Shane Doyle Acute Hospitals Drugs Management Programme, Dublin, Ireland PubMed articles Google scholar articles
Richard W Costello Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland PubMed articles Google scholar articles
Fionnuala King Acute Hospitals Drugs Management Programme, Dublin, Ireland PubMed articles Google scholar articles
Desmond M Murphy Department of Respiratory Medicine, Cork University Hospital, Cork, IrelandThe HRB Clinical Research Facility, University College Cork, Cork, Ireland PubMed articles Google scholar articles

Correspondence to Dr Desmond M Murphy; desmond.murphy{at}hse.ie

View Full Text

Citation

O'Leary C, Schultz C, Walsh C, et al

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

BMJ Open Respiratory Research 2022;9:e001341. doi: 10.1136/bmjresp-2022-001341

Publication history

Received June 21, 2022
Accepted September 4, 2022
First published September 27, 2022.

Online issue publication

October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.